Animal Testing has long been a hot topic in terms of requirements and acceptability. Recent changes in regulations mean it is more important, now than ever to find alternative methods that reduce or eliminate the need for animal testing in ensuring medicines and cosmetics are safe for humans.
This webinar will review the history of animal testing mandates, the reasons why regulations such as the FDA Modernization Act, FDA Center for Veterinary Medicine, and European Union Cosmetology Regulations are changing and will also discuss successful alternative methods that support the 3Rs to reduce, refine, or replace animal testing including Published Literature, In Silico Modeling, 3D Platforms, Organ on a Chip, Cell Tissue Platforms, and Tissue Engineering. 
We’ll be joined by industry experts Gail Van Norman and Thomas Hartung who will share examples of successful regulatory approved approaches. The webinar will end with a live Q&A session.
Gail Van Norman
Professor Emeritus, Department of Anesthesiology and Pain Medicine, University of Washington
Gail Van Norman MD received her doctorate in medicine at the University of Washington in Seattle. She is board-certified in Internal Medicine and in Anaesthesiology, holds a Certificate in Biomedical Ethics from the University of Washington. She is a Professor Emeritus of the Department of Anaesthesiology and Pain Medicine, and until her recent retirement was Adjunct Professor of Biomedical Ethics at the University of Washington. She has also chaired the Committee on Ethics for the American Society of Anaesthesiologists and edited Clinical Ethics for Anaesthesiologists; a Case-Based Textbook published by Cambridge University Press. Dr. Van Norman’s series of articles directed toward drug and device researchers regarding FDA regulatory processes and various research issues concerning medical drugs and devices have been among the most downloaded articles from the Journal of the American College of Cardiology Basic to Translational Science, and her recent article “Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is It Time to Rethink Our Current Approach?” is currently listed among the journal’s top-5 cited articles.
Thomas Hartung
Department of Environmental Health and Engineering at Johns Hopkins Bloomberg School of Public Health, Baltimore
Thomas Hartung, MD PhD, is the Doerenkamp-Zbinden-Chair for Evidence-based Toxicology in the Department of Environmental Health and Engineering at Johns Hopkins Bloomberg School of Public Health, Baltimore, with a joint appointment at the Whiting School of Engineering. He also holds a joint appointment for Molecular Microbiology and Immunology at the Bloomberg School. He is adjunct affiliate professor at Georgetown University, Washington D.C.. In addition, he holds a joint appointment as Professor for Pharmacology and Toxicology at University of Konstanz, Germany; he also is Director of Centers for Alternatives to Animal Testing (CAAT, http://caat.jhsph.edu) of both universities. CAAT hosts the secretariat of the Evidence-based Toxicology Collaboration (http://www.ebtox.org) and manages collaborative programs on Good Read-Across Practice, Good Cell Culture Practice, Green Toxicology, Developmental Neurotoxicity, Developmental Immunotoxicity, Micro physiological Systems and Refinement. As PI, he headed the Human Toxome project funded as an NIH Transformative Research Grant and the series of annual Micro physiological Systems World Summits starting in 2022 by 52 organizations. He is Field Chief Editor of Frontiers in Artificial Intelligence. He is the former Head of the European Commission’s Center for the Validation of Alternative Methods (ECVAM), Ispra, Italy, and has authored more than 620 scientific publications with more than 41,000 citations (h-index 105). His toxicology classes on COURSERA had more than 15,000 active learners.
Michelle Mohsenin RPh
Product Manager, Embase
Michelle Mohsenin Rph is a Product Manager for Elsevier supporting the biomedical journal database, Embase as a Drug Safety/Pharmacovigilance Subject Matter Expert. Prior to Elsevier she was Senior Drug Safety Officer for Pfizer where she led the Global Literature Surveillance group. She was responsible for being regulation compliance to ensure inspection readiness.  She is a licensed New Jersey pharmacist.

Danielle Thomas
Customer Consultant, Elsevier
Danielle has a PhD in Pharmaceutical Sciences and Molecular Biology & Biochemistry. After years of research, working in drug discovery and delivery of chemotherapeutics, Danielle joined Elsevier August of 2021. Currently, Danielle is the Customer Consultant of Life Sciences products, including Embase, PharmaPendium, and QUOSA covering North America. As a Customer Consultant, she is dedicated to assisting scientists and researchers streamline their workflows by providing customized training sessions.
Register To Watch Recording
Full name*
Email Address*
Job Title*
Marketing Permission
Elsevier (https://www.elsevier.com/about/locations) may send you information about relevant products and events. If you do NOT wish to receive such messages please check the box below For more information, please read our privacy policy.
I do not wish to receive marketing emails